[go: up one dir, main page]

WO1998040357A3 - Inhibiteurs de la protease du vih - Google Patents

Inhibiteurs de la protease du vih Download PDF

Info

Publication number
WO1998040357A3
WO1998040357A3 PCT/US1998/004735 US9804735W WO9840357A3 WO 1998040357 A3 WO1998040357 A3 WO 1998040357A3 US 9804735 W US9804735 W US 9804735W WO 9840357 A3 WO9840357 A3 WO 9840357A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv protease
protease inhibitors
hiv
compounds
hiv virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/004735
Other languages
English (en)
Other versions
WO1998040357A2 (fr
Inventor
Kim F Albizati
Siegfried Reich
Michael D Varney
Kanyin E Zhang
Takuo Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Agouron Pharmaceuticals LLC
Original Assignee
Japan Tobacco Inc
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA99008395A priority Critical patent/MXPA99008395A/es
Priority to KR10-1999-7008331A priority patent/KR100511089B1/ko
Priority to HU0001380A priority patent/HUP0001380A3/hu
Priority to SK1222-99A priority patent/SK283636B6/sk
Priority to APAP/P/1999/001648A priority patent/AP1358A/en
Priority to EA199900823A priority patent/EA002378B1/ru
Priority to BR9808867-0A priority patent/BR9808867A/pt
Priority to CA002284163A priority patent/CA2284163A1/fr
Priority to EEP199900416A priority patent/EE04114B1/xx
Priority to IL13187098A priority patent/IL131870A0/xx
Priority to AU64575/98A priority patent/AU743078B2/en
Priority to NZ337706A priority patent/NZ337706A/en
Application filed by Japan Tobacco Inc, Agouron Pharmaceuticals LLC filed Critical Japan Tobacco Inc
Priority to EP98910300A priority patent/EP0970055A2/fr
Priority to JP53974598A priority patent/JP2001516350A/ja
Publication of WO1998040357A2 publication Critical patent/WO1998040357A2/fr
Publication of WO1998040357A3 publication Critical patent/WO1998040357A3/fr
Priority to UA99095049A priority patent/UA57772C2/uk
Priority to IL131870A priority patent/IL131870A/en
Priority to NO19994415A priority patent/NO315555B1/no
Priority to IS5176A priority patent/IS5176A/is
Priority to BG103727A priority patent/BG63540B1/bg
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Ces inhibiteurs de protéases du VIH, que l'on peut obtenir par synthèse chimique, sont capables d'inhiber ou de bloquer l'activité biologique de la protéase du VIH, ce qui provoque l'arrêt de la réplication du virus du VIH. Ces composés, ainsi que les compositions contenant comme principes actifs ces composés et facultativement d'autres agents antiviraux, conviennent au traitement de patients ou d'hôtes infectés par le virus du VIH, qui est connu pour provoquer le SIDA.
PCT/US1998/004735 1997-03-13 1998-03-12 Inhibiteurs de la protease du vih Ceased WO1998040357A2 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
AU64575/98A AU743078B2 (en) 1997-03-13 1998-03-12 HIV protease inhibitors
HU0001380A HUP0001380A3 (en) 1997-03-13 1998-03-12 Isoquinoline derivatives as hiv protease inhibitors, and pharmaceutical compositions containing them
SK1222-99A SK283636B6 (sk) 1997-03-13 1998-03-12 Deriváty dekahydroizochinolínkarboxamidu, farmaceutické prípravky, ktoré ich obsahujú a ich použitie
APAP/P/1999/001648A AP1358A (en) 1997-03-13 1998-03-12 1-Aryl-2-Hydroxy-3-Isoquinoline Carboxamide HIV Protease Inhibitors, Their Preparation and Use.
EA199900823A EA002378B1 (ru) 1997-03-13 1998-03-12 Ингибиторы протеазы вич
KR10-1999-7008331A KR100511089B1 (ko) 1997-03-13 1998-03-12 Ｈｉｖ 프로테아제 억제제
CA002284163A CA2284163A1 (fr) 1997-03-13 1998-03-12 Inhibiteurs de la protease du vih
EEP199900416A EE04114B1 (et) 1997-03-13 1998-03-12 HIV-proteaasi inhibiitorid
IL13187098A IL131870A0 (en) 1997-03-13 1998-03-12 Hiv protease inhibitors
NZ337706A NZ337706A (en) 1997-03-13 1998-03-12 A process for making a HIV protease inhibitor, pharmaceutical composition and salt thereof used in the treatment of the AIDS
BR9808867-0A BR9808867A (pt) 1997-03-13 1998-03-12 Inibidores de hiv protease
MXPA99008395A MXPA99008395A (es) 1997-03-13 1998-03-12 Inhibidores de la proteasa del vih.
EP98910300A EP0970055A2 (fr) 1997-03-13 1998-03-12 Inhibiteurs de la protease du vih
JP53974598A JP2001516350A (ja) 1997-03-13 1998-03-12 Ｈｉｖプロテアーゼインヒビター
UA99095049A UA57772C2 (uk) 1997-03-13 1998-12-03 Інгібітори протеази віл, фармацевтична композиція на їх основі та спосіб інгібування протеази реплікації віл
IL131870A IL131870A (en) 1997-03-13 1999-09-10 History of isoquinoline carboxamide, pharmaceutical preparations containing them and their use in the preparation of drugs to inhibit HIV protease
NO19994415A NO315555B1 (no) 1997-03-13 1999-09-10 HIV proteaseinhibitorer, salt og anvendelse derav, samt farmasöytisk preparat
IS5176A IS5176A (is) 1997-03-13 1999-09-10 Eyðniveiru-próteasa tálmar
BG103727A BG63540B1 (bg) 1997-03-13 1999-09-13 Инхибитори на нiv-протеазата

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81595197A 1997-03-13 1997-03-13
US08/815,951 1997-03-13

Publications (2)

Publication Number Publication Date
WO1998040357A2 WO1998040357A2 (fr) 1998-09-17
WO1998040357A3 true WO1998040357A3 (fr) 1998-11-26

Family

ID=25219265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/004735 Ceased WO1998040357A2 (fr) 1997-03-13 1998-03-12 Inhibiteurs de la protease du vih

Country Status (35)

Country Link
EP (1) EP0970055A2 (fr)
JP (1) JP2001516350A (fr)
KR (1) KR100511089B1 (fr)
CN (1) CN1179948C (fr)
AP (1) AP1358A (fr)
AR (1) AR012556A1 (fr)
AU (1) AU743078B2 (fr)
BG (1) BG63540B1 (fr)
BR (1) BR9808867A (fr)
CA (1) CA2284163A1 (fr)
CO (1) CO4940496A1 (fr)
CZ (1) CZ296647B6 (fr)
EA (1) EA002378B1 (fr)
EE (1) EE04114B1 (fr)
GE (1) GEP20022764B (fr)
HR (1) HRP980112A2 (fr)
HU (1) HUP0001380A3 (fr)
IL (2) IL131870A0 (fr)
IS (1) IS5176A (fr)
MX (1) MXPA99008395A (fr)
MY (1) MY117535A (fr)
NO (1) NO315555B1 (fr)
NZ (1) NZ337706A (fr)
OA (1) OA11196A (fr)
PA (1) PA8448801A1 (fr)
PE (1) PE58799A1 (fr)
PL (1) PL192786B1 (fr)
SA (1) SA98181116B1 (fr)
SK (1) SK283636B6 (fr)
SV (1) SV1998000038A (fr)
TR (1) TR199902508T2 (fr)
TW (1) TW200517112A (fr)
UA (1) UA57772C2 (fr)
WO (1) WO1998040357A2 (fr)
ZA (1) ZA982047B (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009843A1 (fr) * 1993-10-07 1995-04-13 Agouron Pharmaceuticals, Inc. Inhibiteurs de la protease du vih

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009843A1 (fr) * 1993-10-07 1995-04-13 Agouron Pharmaceuticals, Inc. Inhibiteurs de la protease du vih

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARK LONGER ET AL: "Preformulation studies of a novel HIV protease inhibitor,AG1343", JOURNAL OF PHARMACEUTICAL SCIENCES., vol. 84, no. 9, September 1995 (1995-09-01), WASHINGTON US, pages 1090 - 1093, XP002076199 *

Also Published As

Publication number Publication date
EA199900823A1 (ru) 2000-04-24
BG63540B1 (bg) 2002-04-30
AU6457598A (en) 1998-09-29
KR100511089B1 (ko) 2005-08-31
AP1358A (en) 2004-12-03
EE9900416A (et) 2000-04-17
PA8448801A1 (es) 2000-05-24
EP0970055A2 (fr) 2000-01-12
CA2284163A1 (fr) 1998-09-17
CN1179948C (zh) 2004-12-15
HUP0001380A3 (en) 2001-12-28
IL131870A0 (en) 2001-03-19
SV1998000038A (es) 1999-02-15
MY117535A (en) 2004-07-31
SK283636B6 (sk) 2003-11-04
BR9808867A (pt) 2000-07-11
MXPA99008395A (es) 2003-08-12
NO315555B1 (no) 2003-09-22
CO4940496A1 (es) 2000-07-24
TR199902508T2 (xx) 2000-02-21
IL131870A (en) 2006-04-10
ZA982047B (en) 1998-09-28
KR20000076236A (ko) 2000-12-26
SK122299A3 (en) 2000-05-16
NO994415L (no) 1999-11-10
AR012556A1 (es) 2000-11-08
NZ337706A (en) 2001-04-27
AU743078B2 (en) 2002-01-17
WO1998040357A2 (fr) 1998-09-17
EA002378B1 (ru) 2002-04-25
GEP20022764B (en) 2002-08-26
IS5176A (is) 1999-09-10
PL192786B1 (pl) 2006-12-29
BG103727A (bg) 2000-04-28
HRP980112A2 (en) 1998-12-31
HUP0001380A2 (hu) 2000-09-28
CN1253548A (zh) 2000-05-17
NO994415D0 (no) 1999-09-10
UA57772C2 (uk) 2003-07-15
EE04114B1 (et) 2003-08-15
PE58799A1 (es) 1999-07-12
SA98181116B1 (ar) 2006-10-04
TW200517112A (en) 2005-06-01
JP2001516350A (ja) 2001-09-25
AP9901648A0 (en) 1999-09-30
CZ319199A3 (cs) 2000-06-14
PL335672A1 (en) 2000-05-08
CZ296647B6 (cs) 2006-05-17
OA11196A (en) 2003-05-21

Similar Documents

Publication Publication Date Title
EP1340744A3 (fr) Inhibiteurs de la protéase VIH
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
WO2002100844A3 (fr) Inhibiteurs de la protease vih, compositions les contenant, leurs utilisations pharmaceutiques et materiaux utilises pour leur synthese
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
WO2004071426A3 (fr) Composes destines au traitement d'une infection virale
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
NO941937L (no) Sakarinderivater som inhiberer proteolytiske enzymer
WO2004037784A3 (fr) Pyrrolidones ayant une activité anti-vih
ES2132383T3 (es) Inhibidores de proteasa hiv.
MY132553A (en) Methods of making hiv-protease inhibitors and intermediates for making hiv-protease inhibitors
WO1998040357A3 (fr) Inhibiteurs de la protease du vih
WO2003049695A3 (fr) Composes destines a traiter l'infection au vih et le sida
IT1318424B1 (it) Composti con attivita' anti-hiv.
TH14264B (th) ตัวยับยั้ง hiv โพรทิเอส
WO1998009951A3 (fr) Intermediaires permettant la production d'inhibiteurs de la vih-protease et procedes de production d'inhibiteurs de la vih-protease
WO1996013263A3 (fr) Methodes de traitement de maladies virales par des inhibiteurs de la biosynthese des sphingolipides
CA2303591A1 (fr) Methode et compositions pour prevenir ou reduire l'infection par le vih
UA31078A (uk) Інгібітор вірусу імунодефіциту людини ( даримід )

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131870

Country of ref document: IL

Ref document number: P-458/99

Country of ref document: YU

Ref document number: 98804538.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 337706

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 64575/98

Country of ref document: AU

Ref document number: 122299

Country of ref document: SK

Ref document number: PV1999-3191

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2284163

Country of ref document: CA

Ref document number: 2284163

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998910300

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1998 539745

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997008331

Country of ref document: KR

Ref document number: PA/a/1999/008395

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999/02508

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 199900823

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1199900842

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1998910300

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1999-3191

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997008331

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 64575/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1019997008331

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV1999-3191

Country of ref document: CZ